Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015 (2015), Article ID 368053, 3 pages
http://dx.doi.org/10.1155/2015/368053
Case Report

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Department of Dermatology, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark

Received 14 November 2014; Revised 7 January 2015; Accepted 7 January 2015

Academic Editor: Larry W. Moreland

Copyright © 2015 Misbah Nasheela Ghazanfar and Simon Francis Thomsen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Saini, K. E. Rosen, H.-J. Hsieh et al., “A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria,” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 567.e1–573.e1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Zuberbier, W. Aberer, and R. Asero, “The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update,” Allergy, vol. 69, no. 7, pp. 868–887, 2014. View at Publisher · View at Google Scholar
  3. M. Maurer, S. Altrichter, T. Bieber et al., “Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase,” Journal of Allergy and Clinical Immunology, vol. 128, no. 1, pp. 202–209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Saini, K. E. Rosen, H.-J. Hsieh et al., “A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H 1-antihistamine-refractory chronic idiopathic urticaria,” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 567–573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Maurer, K. Rosen, H. Hsieh et al., “Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria,” The New England Journal of Medicine, vol. 368, pp. 924–935, 2013. View at Publisher · View at Google Scholar
  6. A. Kaplan, D. Ledford, M. Ashby et al., “Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy,” Journal of Allergy and Clinical Immunology, vol. 132, no. 1, pp. 101–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. S. Saini, C. Bindslev-Jensen, M. Maurer et al., “Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study,” Journal of Investigative Dermatology, 2014. View at Publisher · View at Google Scholar
  8. A. P. Kaplan, K. Joseph, R. J. Maykut, G. P. Geba, and R. K. Zeldin, “Treatment of chronic autoimmune urticaria with omalizumab,” Journal of Allergy and Clinical Immunology, vol. 122, no. 3, pp. 569–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Vieira dos Santos, B. Locks Bidese, J. Rabello de Souza, and M. Maurer, “Effects of omalizumab in a patient with three types of chronic urticaria,” British Journal of Dermatology, vol. 170, no. 2, pp. 469–471, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Namazy, M. D. Cabana, A. E. Scheuerle et al., “The xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy,” The Journal of Allergy and Clinical Immunology, 2014. View at Publisher · View at Google Scholar